Evidence map›Paper›PMID 42048601›Full record

Trial reportHuman vaccines & immunotherapeutics2026

Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.

Emily Comstock, Charles Fogarty, Jorge Caso, Jack Vu, Ambrish Sinha, Xin Cao, HuiLing Chen, Lee Rushton, Chong Ma, Frances Priddy

Abstract readClinical Trial, Phase IIIEquivalence TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emily ComstockModerna, Inc., Cambridge, MA, USA.
Charles FogartySpartanburg Medical Research, Spartanburg, SC, USA.
Jorge CasoSuncoast Research Associates, Miami, FL, USA.
Jack VuArtemis Institute for Clinical Research, Riverside, CA, USA.
Ambrish SinhaModerna, Inc., Cambridge, MA, USA.
Xin CaoModerna, Inc., Cambridge, MA, USA.
HuiLing ChenModerna, Inc., Cambridge, MA, USA.
Lee RushtonModerna, Inc., Cambridge, MA, USA.
Chong MaModerna, Inc., Cambridge, MA, USA.
Frances PriddyModerna, Inc., Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coadministration of respiratory syncytial virus (RSV) and seasonal influenza vaccines can increase vaccination uptake. mRNA-1345 (mRESVIA, Moderna, Inc.) is indicated in multiple countries for prevention of RSV-lower respiratory tract disease in adults. This randomized, observer-blind, phase 3 study evaluated safety, tolerability, immunogenicity, and inferred efficacy of mRNA-1345 when coadministered with quadrivalent influenza vaccine-high dose (QIV-HD). Adults ≥65 y (

Indexed as

Influenza, HumanInfluenza VaccinesmRNA VaccinesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralFemaleHumansMaleSingle-Blind MethodVaccine EfficacyAntibodies, NeutralizingAntibodies, ViralInfluenza VaccinesmRNA-1345 respiratory syncytial virus vaccinemRNA VaccinesRespiratory Syncytial Virus VaccinesCoadministrationimmunogenicityinfluenzamRNA-1345mRNA vaccinerespiratory syncytial virus

Identifiers

PMID42048601
PMCPMC13128023

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.